As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.
10 Analysts have issued a IN8bio Inc forecast:
10 Analysts have issued a IN8bio Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -21 -21 |
31%
31%
|
EBIT (Operating Income) EBIT | -24 -24 |
25%
25%
|
Net Profit | -24 -24 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Head office | United States |
CEO | William Ho |
Employees | 18 |
Founded | 2016 |
Website | www.in8bio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.